Future of toxicogenomics and safety signatures: balancing public access to data with proprietary drug discovery-Reference-Cited by-同舟云学术

Future of toxicogenomics and safety signatures: balancing public access to data with proprietary drug discovery

Published:2007-05 Issue:5 Volume:8 Page:425-430
ISSN:1462-2416
Container-title:Pharmacogenomics
language:en
Short-container-title:Pharmacogenomics

Author:

Fostel Jennifer M¹

Affiliation:

1. US National Center for Toxicogenomics, National Institute of Environmental Health Sciences, LMIT ITSS Contract, F1-05, 111 Alexander Drive, PO Box 12233, Research Triangle Park, NC 27709-2233, USA.

Publisher

Future Medicine Ltd

Subject

Pharmacology,Genetics,Molecular Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/14622416.8.5.425

Reference53 articles.

1. Gene Expression Analysis Reveals Chemical-Specific Profiles

2. BGX: a fully Bayesian integrated approach to the analysis of Affymetrix GeneChip data

3. Translational medicine: the discovery of bridging biomarkers using pharmacogenomics

4. Iconix Pharmaceuticals, Inc. – removing barriers to efficient drug discovery through chemogenomics

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Systems Biology and Biomarkers of Early Effects for Occupational Exposure Limit Setting;Journal of Occupational and Environmental Hygiene;2015-11-19

2. Heading Down the Wrong Pathway: on the Influence of Correlation within Gene Sets;BMC Genomics;2010-10-18

3. Toxicogenetics: population-based testing of drug and chemical safety in mouse models;Pharmacogenomics;2010-08

4. Toxicogenetics: population-based testing of drug and chemical safety in mouse models;Pharmacogenomics;2010-08

5. The Potential of Embryonic Stem Cells Combined with -omics Technologies as Model Systems for Toxicology;Current Medicinal Chemistry;2009-12-01